SciTech Development LLC is a specialty pharmaceutical company that has developed a patented nanoparticle drug delivery platform (SDP) that maximizes the bioavailability of water-insoluble therapeutics. SciTech's lead drug candidate, ST-001 nanoFenretinide, combines the delivery system with fenretinide as a broadly applicable cancer-fighting drug. ST-001 has FDA Investigational New Drug (IND) approval and Orphan Drug designation.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 06/07/23 | $2,730,000 |
HRN Family Office Pointe Angels Storm Lake Capital The National Foundation for Cancer Research | undisclosed |
